What's new? Log in Free sign up

Karuna Therapeutics (KRTX) News and press releases

Company Profile

News

From Benzinga Pro

HC Wainwright & Co. Maintains Buy on Karuna Therapeutics, Lowers Price Target to $300

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Karuna Therapeutics (NASDAQ:KRTX) with a Buy and lowers the price target from $320 to $300.

Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.

Travelzoo, Semler Scientific, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday

News, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

U.S. stocks traded mostly higher, with the Dow Jones gaining around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.

Reported Late Tuesday March 21, Karuna Therapeutics Announces Pricing Of $400M Public Offering Of 2,479,391 Shares Of Common Stock At A Price Of $161.33/Share

News, Offerings

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced

Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.

Analyst Expectations for Karuna Therapeutics's Future

Analyst Ratings

JMP Securities Reiterates Market Outperform on Karuna Therapeutics, Maintains $323 Price Target

News, Price Target, Reiteration, Analyst Ratings

JMP Securities analyst Jason Butler reiterates Karuna Therapeutics (NASDAQ:KRTX) with a Market Outperform and maintains $323 price target.

Wedbush Maintains Outperform on Karuna Therapeutics

News, Analyst Ratings

Wedbush analyst Laura Chico maintains Karuna Therapeutics (NASDAQ:KRTX) with a Outperform.

Karuna Therapeutics Says It One Step Closer To Potential Treatment Option After Encouraging Schizophrenia Data

Biotech, News, Health Care, Movers, Trading Ideas, General

Karuna Therapeutics's Phase 3 EMERGENT-3 Trial Of KarXT (Xanomeline-trospium) In Adults With Schizophrenia, Met Its Primary Endpoint, With KarXT Demonstrating A 8.4-point Reduction In Positive And Negative Syndrome Scale Total Score Compared To Placebo

Biotech, News, Health Care, General

The NDA submission for KarXT in schizophrenia will incorporate the efficacy and safety data from the three placebo-controlled registrational trials, EMERGENT-1, EMERGENT-2, and EMERGENT-3, in addition to long-term safety

Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Cantor Fitzgerald Initiates Coverage On Karuna Therapeutics with Neutral Rating, Announces Price Target of $214

News, Price Target, Initiation, Analyst Ratings

Cantor Fitzgerald analyst Charles Duncan initiates coverage on Karuna Therapeutics (NASDAQ:KRTX) with a Neutral rating and announces Price Target of $214.

Ciena, Apple And 3 Stocks To Watch Heading Into Monday

Earnings, News, Small Cap, Pre-Market Outlook, Markets, Trading Ideas

With US futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Target To Rally 20%? Here Are 10 Other Analyst Forecasts For Thursday

News, Price Target, Small Cap, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas

Bernstein raised the price target for Okta, Inc. (NASDAQ: OKTA) from $80 to $92. Bernstein analyst Peter Weed maintained a Market Perform rating. Okta shares jumped 16.2% to $83.00 in pre-market trading.

The Latest Analyst Ratings for Karuna Therapeutics

Analyst Ratings

Wells Fargo Reiterates Overweight on Karuna Therapeutics, Lowers Price Target to $257

News, Price Target, Reiteration, Analyst Ratings

Wells Fargo analyst Jacob Hughes reiterates Karuna Therapeutics (NASDAQ:KRTX) with a Overweight and lowers the price target from $262 to $257.

Looking Into Karuna Therapeutics's Return On Capital Employed

HC Wainwright & Co. Reiterates Buy on Karuna Therapeutics, Maintains $320 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Karuna Therapeutics (NASDAQ:KRTX) with a Buy and maintains $320 price target.

Karuna Therapeutics Q4 EPS $(2.22) Beats $(2.25) Estimate, Sales $5.28M Not Comparable To $10.00K Estimate

Karuna Therapeutics (NASDAQ:KRTX) reported quarterly losses of $(2.22) per share which beat the analyst consensus estimate of $(2.25) by 1.33 percent. This is a 136.17 percent decrease over losses of $(0.94) per share

Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'

Analyst Color, Biotech, News, Health Care, Contracts, Analyst Ratings, Trading Ideas, General

Press releases

From Benzinga Pro

Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Karuna Therapeutics, Inc. (NASDAQ:KRTX) ("Karuna"), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today

Karuna Therapeutics to Present at the Stifel 2023 CNS Days

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced

Thinking about trading options or stock in Spotify, Winnebago, Apple, Karuna Therapeutics, or Anheuser-Busch?

Opinion, Press Releases

NEW YORK, March 22, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPOT, WGO, AAPL, KRTX, and BUD.

Karuna Therapeutics Announces Pricing of Public Offering of Common Stock

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced

Karuna Therapeutics Announces Proposed Public Offering of Common Stock

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

Press Releases, General

Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well tolerated, with a

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well tolerated, with a

Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates

Topline data from Phase 3 EMERGENT-3 trial anticipated in the first quarter of 2023 On track to submit New Drug Application (NDA) for KarXT in schizophrenia to the U.S. Food & Drug Administration (FDA) in

Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced

Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio's Investigational TRPC4/5 Product Candidates

Karuna to obtain exclusive global license to develop, manufacture, and commercialize multiple TRPC4/5 candidates, including lead clinical-stage candidate GFB-887 Goldfinch Bio assignment estate to receive $15 million

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced

Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced

Moore Kuehn, PLLC Encourages Investors of Karuna Therapeutics, Inc. to Contact Law Firm

NEW YORK, Dec. 29, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Karuna Therapeutics, Inc. (NASDAQ:KRTX) breached their

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.